A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor

Clinical trial NCT07612891 · RECRUITING

Trial details

NCT number: NCT07612891
Sponsor: Shenzhen Ionova Life Sciences Co., Ltd.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Breast Cancer (Locally Advanced or Metastatic)Advanced Solid Cancers Metastatic (Stage IV) Breast Cancer Ovarian Cancer Endometrial Cancer

Start date: 2025-07-04
Primary completion: 2028-02-04
Enrollment: 201

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.